Retail investors crowd into Eli Lilly after weight-loss drug approval
Reuters
Published Nov 17, 2023 08:04AM ET
By Bhanvi Satija and Amruta Khandekar
(Reuters) - Retail flows into Eli Lilly (NYSE:LLY) spiked to a more than two-year high in November, as small investors rushed to buy the stock after the U.S. pharma major received a highly anticipated approval for its weight-loss drug Zepbound. Daily net purchases surged to $14.4 million on Nov. 8, when Zepbound was cleared in the U.S. and the U.K., hitting their highest levels since January 2021, as per data from Vanda (NASDAQ:VNDA) Research.
Lilly and Novo Nordisk (NYSE:NVO) - seen as leaders in a potential $100 billion obesity treatment market - have helped rekindle retail investor interest in the healthcare sector.
"During the COVID period, retail investors were piling into healthcare because of the vaccines and after that there was a bit of a hangover of purchases. But now with these (weight-loss) drugs, some of it is returning," said Marco Iachini, senior vice president of research at Vanda Research.
Retail investors are now "catching up" with institutional investors, said Sel Hardy, vice president of equity research at CFRA.
"(Eli Lilly) is almost becoming a household name. A lot of people know about the obesity drug now and the increasing interest and its success," added Hardy.
Heavyweight investors such as JPMorgan Chase (NYSE:JPM) and BlackRock (NYSE:BLK) had increased their holdings in the stock in the third quarter.
Lilly's shares have climbed 61% year-to-date, trading nearly 50 times their 12-month forward earnings, compared with 27.57 times for the U.S. healthcare sector, according to LSEG data.
Net retail purchases of Novo Nordisk shares hit an all-time high in October, according to Vanda data, after its diabetes drug Ozempic showed early success in a trial to treat kidney failure in diabetes patients.
Novo's American Depository Receipts (ADRs) have risen 47% so far this year.
The surge in interest for the weight-loss drugmakers comes despite a recent decline in overall retail flows to U.S exchanges as the holiday season approaches.
Still, the inflows remain below some of the popular tech stocks like Roblox and AMC, Iachini added.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.